APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pharma Sustained Release Agent

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pharma Sustained Release Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025198 pages

Choose your research edition.

Industry ResearchPharma Sustained Release Agent Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Pharma Sustained Release Agent Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Pharma Sustained Release Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pharma Sustained Release Agent Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Pharma Sustained Release Agent Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Pharma Sustained Release Agent market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Pharma Sustained Release Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pharma Sustained Release Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pharma Sustained Release Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Pharma Sustained Release Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pharma Sustained Release Agent include Janssen Pharmaceuticals, Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, Novartis AG, Merck KGaA, Mylan N.V., Pfizer, GlaxoSmithKline and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pharma Sustained Release Agent market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pharma Sustained Release Agent and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pharma Sustained Release Agent sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pharma Sustained Release Agent market size, projected growth trends, production technologies, key applications, and end-use industries.

Pharma Sustained Release Agent Segment by Company

Janssen Pharmaceuticals

Teva Pharmaceutical Industries

Sun Pharmaceutical Industries

Novartis AG

Merck KGaA

Mylan N.V.

Pfizer

GlaxoSmithKline

AstraZeneca

Valeant Pharmaceuticals International

Mayne Pharma Group

International Flavors & Fragrances

Gattefosse

Evonik Industries

Croda International

BASF

Ashland Global

Allergan

Pharma Sustained Release Agent Segment by Type

Sugars

Gelatin

Minerals

Chitosan

Polymers

Pharma Sustained Release Agent Segment by Application

Pharmaceutical

Health Care

Others

Pharma Sustained Release Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharma Sustained Release Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pharma Sustained Release Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharma Sustained Release Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pharma Sustained Release Agent market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pharma Sustained Release Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Pharma Sustained Release Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Pharma Sustained Release Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Pharma Sustained Release Agent Industry Trends Table 2. Pharma Sustained Release Agent Industry Drivers Table 3. Pharma Sustained Release Agent Industry Opportunities and Challenges Table 4. Pharma Sustained Release Agent Industry Restraints Table 5. Global Pharma Sustained Release Agent Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Pharma Sustained Release Agent Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Pharma Sustained Release Agent Sales by Manufacturers (k tons) & (2021-2026) Table 8. Global Pharma Sustained Release Agent Sales Market Share by Manufacturers Table 9. Global Pharma Sustained Release Agent Average Sales Price (US$/ton) of Manufacturers (2021-2026) Table 10. Global Pharma Sustained Release Agent Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Pharma Sustained Release Agent Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Pharma Sustained Release Agent Manufacturers, Product Type & Application Table 13. Global Pharma Sustained Release Agent Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Pharma Sustained Release Agent by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Sugars Table 17. Major Manufacturers of Gelatin Table 18. Major Manufacturers of Minerals Table 19. Major Manufacturers of Chitosan Table 20. Major Manufacturers of Polymers Table 21. Global Pharma Sustained Release Agent Sales by Type 2021 VS 2025 VS 2032 (k tons) Table 22. Global Pharma Sustained Release Agent Sales by Type (2021-2026) & (k tons) Table 23. Global Pharma Sustained Release Agent Sales by Type (2027-2032) & (k tons) Table 24. Global Pharma Sustained Release Agent Sales Market Share by Type (2021-2026) Table 25. Global Pharma Sustained Release Agent Sales Market Share by Type (2027-2032) Table 26. Global Pharma Sustained Release Agent Revenue by Type 2021 VS 2025 VS 2032 (k tons) Table 27. Global Pharma Sustained Release Agent Revenue by Type (2021-2026) & (k tons) Table 28. Global Pharma Sustained Release Agent Revenue by Type (2027-2032) & (k tons) Table 29. Global Pharma Sustained Release Agent Revenue Market Share by Type (2021-2026) Table 30. Global Pharma Sustained Release Agent Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Pharmaceutical Table 32. Major Manufacturers of Health Care Table 33. Major Manufacturers of Others Table 34. Global Pharma Sustained Release Agent Sales by Application 2021 VS 2025 VS 2032 (k tons) Table 35. Global Pharma Sustained Release Agent Sales by Application (2021-2026) & (k tons) Table 36. Global Pharma Sustained Release Agent Sales by Application (2027-2032) & (k tons) Table 37. Global Pharma Sustained Release Agent Sales Market Share by Application (2021-2026) Table 38. Global Pharma Sustained Release Agent Sales Market Share by Application (2027-2032) Table 39. Global Pharma Sustained Release Agent Revenue by Application 2021 VS 2025 VS 2032 (k tons) Table 40. Global Pharma Sustained Release Agent Revenue by Application (2021-2026) & (k tons) Table 41. Global Pharma Sustained Release Agent Revenue by Application (2027-2032) & (k tons) Table 42. Global Pharma Sustained Release Agent Revenue Market Share by Application (2021-2026) Table 43. Global Pharma Sustained Release Agent Revenue Market Share by Application (2027-2032) Table 44. Global Pharma Sustained Release Agent Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 45. Global Pharma Sustained Release Agent Sales by Region (2021-2026) & (k tons) Table 46. Global Pharma Sustained Release Agent Sales Market Share by Region (2021-2026) Table 47. Global Pharma Sustained Release Agent Sales Forecasted by Region (2027-2032) & (k tons) Table 48. Global Pharma Sustained Release Agent Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Pharma Sustained Release Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 50. North America Pharma Sustained Release Agent Sales by Country (2021-2026) & (k tons) Table 51. North America Pharma Sustained Release Agent Sales by Country (2027-2032) & (k tons) Table 52. Europe Pharma Sustained Release Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 53. Europe Pharma Sustained Release Agent Sales by Country (2021-2026) & (k tons) Table 54. Europe Pharma Sustained Release Agent Sales by Country (2027-2032) & (k tons) Table 55. Asia Pacific Pharma Sustained Release Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 56. Asia Pacific Pharma Sustained Release Agent Sales by Country (2021-2026) & (k tons) Table 57. Asia Pacific Pharma Sustained Release Agent Sales by Country (2027-2032) & (k tons) Table 58. South America, Middle East and Africa Pharma Sustained Release Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 59. South America, Middle East and Africa Pharma Sustained Release Agent Sales by Country (2021-2026) & (k tons) Table 60. South America, Middle East and Africa Pharma Sustained Release Agent Sales by Country (2027-2032) & (k tons) Table 61. Global Pharma Sustained Release Agent Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Pharma Sustained Release Agent Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Pharma Sustained Release Agent Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Pharma Sustained Release Agent Revenue Market Share by Region (2021-2026) Table 65. Global Pharma Sustained Release Agent Revenue Market Share by Region (2027-2032) Table 66. Janssen Pharmaceuticals Company Information Table 67. Janssen Pharmaceuticals Business Overview Table 68. Janssen Pharmaceuticals Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Janssen Pharmaceuticals Pharma Sustained Release Agent Product Portfolio Table 70. Janssen Pharmaceuticals Recent Development Table 71. Teva Pharmaceutical Industries Company Information Table 72. Teva Pharmaceutical Industries Business Overview Table 73. Teva Pharmaceutical Industries Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Teva Pharmaceutical Industries Pharma Sustained Release Agent Product Portfolio Table 75. Teva Pharmaceutical Industries Recent Development Table 76. Sun Pharmaceutical Industries Company Information Table 77. Sun Pharmaceutical Industries Business Overview Table 78. Sun Pharmaceutical Industries Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Sun Pharmaceutical Industries Pharma Sustained Release Agent Product Portfolio Table 80. Sun Pharmaceutical Industries Recent Development Table 81. Novartis AG Company Information Table 82. Novartis AG Business Overview Table 83. Novartis AG Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Novartis AG Pharma Sustained Release Agent Product Portfolio Table 85. Novartis AG Recent Development Table 86. Merck KGaA Company Information Table 87. Merck KGaA Business Overview Table 88. Merck KGaA Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Merck KGaA Pharma Sustained Release Agent Product Portfolio Table 90. Merck KGaA Recent Development Table 91. Mylan N.V. Company Information Table 92. Mylan N.V. Business Overview Table 93. Mylan N.V. Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Mylan N.V. Pharma Sustained Release Agent Product Portfolio Table 95. Mylan N.V. Recent Development Table 96. Pfizer Company Information Table 97. Pfizer Business Overview Table 98. Pfizer Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Pfizer Pharma Sustained Release Agent Product Portfolio Table 100. Pfizer Recent Development Table 101. GlaxoSmithKline Company Information Table 102. GlaxoSmithKline Business Overview Table 103. GlaxoSmithKline Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. GlaxoSmithKline Pharma Sustained Release Agent Product Portfolio Table 105. GlaxoSmithKline Recent Development Table 106. AstraZeneca Company Information Table 107. AstraZeneca Business Overview Table 108. AstraZeneca Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. AstraZeneca Pharma Sustained Release Agent Product Portfolio Table 110. AstraZeneca Recent Development Table 111. Valeant Pharmaceuticals International Company Information Table 112. Valeant Pharmaceuticals International Business Overview Table 113. Valeant Pharmaceuticals International Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Valeant Pharmaceuticals International Pharma Sustained Release Agent Product Portfolio Table 115. Valeant Pharmaceuticals International Recent Development Table 116. Mayne Pharma Group Company Information Table 117. Mayne Pharma Group Business Overview Table 118. Mayne Pharma Group Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Mayne Pharma Group Pharma Sustained Release Agent Product Portfolio Table 120. Mayne Pharma Group Recent Development Table 121. International Flavors & Fragrances Company Information Table 122. International Flavors & Fragrances Business Overview Table 123. International Flavors & Fragrances Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. International Flavors & Fragrances Pharma Sustained Release Agent Product Portfolio Table 125. International Flavors & Fragrances Recent Development Table 126. Gattefosse Company Information Table 127. Gattefosse Business Overview Table 128. Gattefosse Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Gattefosse Pharma Sustained Release Agent Product Portfolio Table 130. Gattefosse Recent Development Table 131. Evonik Industries Company Information Table 132. Evonik Industries Business Overview Table 133. Evonik Industries Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Evonik Industries Pharma Sustained Release Agent Product Portfolio Table 135. Evonik Industries Recent Development Table 136. Croda International Company Information Table 137. Croda International Business Overview Table 138. Croda International Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Croda International Pharma Sustained Release Agent Product Portfolio Table 140. Croda International Recent Development Table 141. BASF Company Information Table 142. BASF Business Overview Table 143. BASF Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. BASF Pharma Sustained Release Agent Product Portfolio Table 145. BASF Recent Development Table 146. Ashland Global Company Information Table 147. Ashland Global Business Overview Table 148. Ashland Global Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Ashland Global Pharma Sustained Release Agent Product Portfolio Table 150. Ashland Global Recent Development Table 151. Allergan Company Information Table 152. Allergan Business Overview Table 153. Allergan Pharma Sustained Release Agent Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. Allergan Pharma Sustained Release Agent Product Portfolio Table 155. Allergan Recent Development Table 156. Key Raw Materials Table 157. Raw Materials Key Suppliers Table 158. Pharma Sustained Release Agent Distributors List Table 159. Pharma Sustained Release Agent Customers List Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. Pharma Sustained Release Agent Product Image Figure 2. Global Pharma Sustained Release Agent Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pharma Sustained Release Agent Market Size (2021-2032) & (US$ Million) Figure 4. Global Pharma Sustained Release Agent Sales (2021-2032) & (k tons) Figure 5. Global Pharma Sustained Release Agent Average Price (US$/ton) & (2021-2032) Figure 6. Global Top 5 and 10 Pharma Sustained Release Agent Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Sugars Image Figure 9. Gelatin Image Figure 10. Minerals Image Figure 11. Chitosan Image Figure 12. Polymers Image Figure 13. Global Pharma Sustained Release Agent Sales by Type (2021 VS 2025 VS 2032) & (k tons) Figure 14. Global Pharma Sustained Release Agent Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Pharma Sustained Release Agent Sales Market Share by Type (2021-2032) Figure 16. Global Pharma Sustained Release Agent Revenue by Type (2021 VS 2025 VS 2032) & (k tons) Figure 17. Global Pharma Sustained Release Agent Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Pharma Sustained Release Agent Revenue Market Share by Type (2021-2032) Figure 19. Pharmaceutical Image Figure 20. Health Care Image Figure 21. Others Image Figure 22. Global Pharma Sustained Release Agent Sales by Application (2021 VS 2025 VS 2032) & (k tons) Figure 23. Global Pharma Sustained Release Agent Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Pharma Sustained Release Agent Sales Market Share by Application (2021-2032) Figure 25. Global Pharma Sustained Release Agent Revenue by Application (2021 VS 2025 VS 2032) & (k tons) Figure 26. Global Pharma Sustained Release Agent Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Pharma Sustained Release Agent Revenue Market Share by Application (2021-2032) Figure 28. North America Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 29. North America Pharma Sustained Release Agent Sales Market Share by Country (2021-2032) Figure 30. U.S. Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 31. Canada Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 32. Mexico Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 33. Europe Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 34. Europe Pharma Sustained Release Agent Sales Market Share by Country (2021-2032) Figure 35. Germany Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 36. France Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 37. U.K. Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 38. Italy Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 39. Netherlands Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 40. Asia Pacific Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 41. Asia Pacific Pharma Sustained Release Agent Sales Market Share by Country (2021-2032) Figure 42. China Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 43. Japan Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 44. South Korea Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 45. Southeast Asia Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 46. India Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 47. Australia Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 48. South America, Middle East and Africa Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 49. South America, Middle East and Africa Pharma Sustained Release Agent Sales Market Share by Country (2021-2032) Figure 50. Brazil Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 51. South Africa Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 52. Saudi Arabia Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 53. Turkey Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 54. Argentina Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 55. UAE Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 56. Egypt Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 57. Chile Pharma Sustained Release Agent Sales and Growth Rate (2021-2032) & (k tons) Figure 58. Global Pharma Sustained Release Agent Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Pharma Sustained Release Agent Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Pharma Sustained Release Agent Revenue (2021-2032) & (US$ Million) Figure 61. North America Pharma Sustained Release Agent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Pharma Sustained Release Agent Revenue (2021-2032) & (US$ Million) Figure 63. Europe Pharma Sustained Release Agent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Pharma Sustained Release Agent Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Pharma Sustained Release Agent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Pharma Sustained Release Agent Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Pharma Sustained Release Agent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Pharma Sustained Release Agent Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Pharma Sustained Release Agent Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Sugars
  • Gelatin
  • Minerals
  • Chitosan
  • Polymers
Applications
  • Pharmaceutical
  • Health Care
  • Others
Companies covered
  • Janssen Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Sun Pharmaceutical Industries
  • Novartis AG
  • Merck KGaA
  • Mylan N.V.
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Valeant Pharmaceuticals International
  • Mayne Pharma Group
  • International Flavors & Fragrances
  • Gattefosse
  • Evonik Industries
  • Croda International
  • BASF
  • Ashland Global
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pharma Sustained Release Agent Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pharma Sustained Release Agent Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Pharma Sustained Release Agent Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Pharma Sustained Release Agent Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Pharma Sustained Release Agent Market Dynamics
  1. 2.1 Pharma Sustained Release Agent Industry Trends
  2. 2.2 Pharma Sustained Release Agent Industry Drivers
  3. 2.3 Pharma Sustained Release Agent Industry Opportunities and Challenges
  4. 2.4 Pharma Sustained Release Agent Industry Restraints
3 Pharma Sustained Release Agent Market by Manufacturers
  1. 3.1 Global Pharma Sustained Release Agent Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Pharma Sustained Release Agent Sales by Manufacturers (2021-2026)
  3. 3.3 Global Pharma Sustained Release Agent Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Pharma Sustained Release Agent Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pharma Sustained Release Agent Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Pharma Sustained Release Agent Manufacturers, Product Type & Application
  7. 3.7 Global Pharma Sustained Release Agent Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pharma Sustained Release Agent Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pharma Sustained Release Agent Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pharma Sustained Release Agent Tier 1, Tier 2, and Tier 3
4 Pharma Sustained Release Agent Market by Type
  1. 4.1 Pharma Sustained Release Agent Type Introduction
  2. 4.1.1 Sugars
  3. 4.1.2 Gelatin
  4. 4.1.3 Minerals
  5. 4.1.4 Chitosan
  6. 4.1.5 Polymers
  7. 4.2 Global Pharma Sustained Release Agent Sales by Type
  8. 4.2.1 Global Pharma Sustained Release Agent Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Pharma Sustained Release Agent Sales by Type (2021-2032)
  10. 4.2.3 Global Pharma Sustained Release Agent Sales Market Share by Type (2021-2032)
  11. 4.3 Global Pharma Sustained Release Agent Revenue by Type
  12. 4.3.1 Global Pharma Sustained Release Agent Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Pharma Sustained Release Agent Revenue by Type (2021-2032)
  14. 4.3.3 Global Pharma Sustained Release Agent Revenue Market Share by Type (2021-2032)
5 Pharma Sustained Release Agent Market by Application
  1. 5.1 Pharma Sustained Release Agent Application Introduction
  2. 5.1.1 Pharmaceutical
  3. 5.1.2 Health Care
  4. 5.1.3 Others
  5. 5.2 Global Pharma Sustained Release Agent Sales by Application
  6. 5.2.1 Global Pharma Sustained Release Agent Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pharma Sustained Release Agent Sales by Application (2021-2032)
  8. 5.2.3 Global Pharma Sustained Release Agent Sales Market Share by Application (2021-2032)
  9. 5.3 Global Pharma Sustained Release Agent Revenue by Application
  10. 5.3.1 Global Pharma Sustained Release Agent Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pharma Sustained Release Agent Revenue by Application (2021-2032)
  12. 5.3.3 Global Pharma Sustained Release Agent Revenue Market Share by Application (2021-2032)
6 Global Pharma Sustained Release Agent Sales by Region
  1. 6.1 Global Pharma Sustained Release Agent Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pharma Sustained Release Agent Sales by Region (2021-2032)
  3. 6.2.1 Global Pharma Sustained Release Agent Sales by Region (2021-2026)
  4. 6.2.2 Global Pharma Sustained Release Agent Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pharma Sustained Release Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Pharma Sustained Release Agent Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Pharma Sustained Release Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Pharma Sustained Release Agent Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Pharma Sustained Release Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Pharma Sustained Release Agent Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Pharma Sustained Release Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Pharma Sustained Release Agent Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Pharma Sustained Release Agent Revenue by Region
  1. 7.1 Global Pharma Sustained Release Agent Revenue by Region
  2. 7.1.1 Global Pharma Sustained Release Agent Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Pharma Sustained Release Agent Revenue by Region (2021-2026)
  4. 7.1.3 Global Pharma Sustained Release Agent Revenue by Region (2027-2032)
  5. 7.1.4 Global Pharma Sustained Release Agent Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Pharma Sustained Release Agent Revenue (2021-2032)
  8. 7.2.2 North America Pharma Sustained Release Agent Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Pharma Sustained Release Agent Revenue (2021-2032)
  11. 7.3.2 Europe Pharma Sustained Release Agent Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Pharma Sustained Release Agent Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Pharma Sustained Release Agent Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Pharma Sustained Release Agent Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Pharma Sustained Release Agent Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Janssen Pharmaceuticals
  2. 8.1.1 Janssen Pharmaceuticals Company Information
  3. 8.1.2 Janssen Pharmaceuticals Business Overview
  4. 8.1.3 Janssen Pharmaceuticals Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Janssen Pharmaceuticals Pharma Sustained Release Agent Product Portfolio
  6. 8.1.5 Janssen Pharmaceuticals Recent Developments
  7. 8.2 Teva Pharmaceutical Industries
  8. 8.2.1 Teva Pharmaceutical Industries Company Information
  9. 8.2.2 Teva Pharmaceutical Industries Business Overview
  10. 8.2.3 Teva Pharmaceutical Industries Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Pharmaceutical Industries Pharma Sustained Release Agent Product Portfolio
  12. 8.2.5 Teva Pharmaceutical Industries Recent Developments
  13. 8.3 Sun Pharmaceutical Industries
  14. 8.3.1 Sun Pharmaceutical Industries Company Information
  15. 8.3.2 Sun Pharmaceutical Industries Business Overview
  16. 8.3.3 Sun Pharmaceutical Industries Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sun Pharmaceutical Industries Pharma Sustained Release Agent Product Portfolio
  18. 8.3.5 Sun Pharmaceutical Industries Recent Developments
  19. 8.4 Novartis AG
  20. 8.4.1 Novartis AG Company Information
  21. 8.4.2 Novartis AG Business Overview
  22. 8.4.3 Novartis AG Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis AG Pharma Sustained Release Agent Product Portfolio
  24. 8.4.5 Novartis AG Recent Developments
  25. 8.5 Merck KGaA
  26. 8.5.1 Merck KGaA Company Information
  27. 8.5.2 Merck KGaA Business Overview
  28. 8.5.3 Merck KGaA Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck KGaA Pharma Sustained Release Agent Product Portfolio
  30. 8.5.5 Merck KGaA Recent Developments
  31. 8.6 Mylan N.V.
  32. 8.6.1 Mylan N.V. Company Information
  33. 8.6.2 Mylan N.V. Business Overview
  34. 8.6.3 Mylan N.V. Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Mylan N.V. Pharma Sustained Release Agent Product Portfolio
  36. 8.6.5 Mylan N.V. Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Pharma Sustained Release Agent Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 GlaxoSmithKline
  44. 8.8.1 GlaxoSmithKline Company Information
  45. 8.8.2 GlaxoSmithKline Business Overview
  46. 8.8.3 GlaxoSmithKline Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GlaxoSmithKline Pharma Sustained Release Agent Product Portfolio
  48. 8.8.5 GlaxoSmithKline Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Pharma Sustained Release Agent Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
  55. 8.10 Valeant Pharmaceuticals International
  56. 8.10.1 Valeant Pharmaceuticals International Company Information
  57. 8.10.2 Valeant Pharmaceuticals International Business Overview
  58. 8.10.3 Valeant Pharmaceuticals International Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Valeant Pharmaceuticals International Pharma Sustained Release Agent Product Portfolio
  60. 8.10.5 Valeant Pharmaceuticals International Recent Developments
  61. 8.11 Mayne Pharma Group
  62. 8.11.1 Mayne Pharma Group Company Information
  63. 8.11.2 Mayne Pharma Group Business Overview
  64. 8.11.3 Mayne Pharma Group Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Mayne Pharma Group Pharma Sustained Release Agent Product Portfolio
  66. 8.11.5 Mayne Pharma Group Recent Developments
  67. 8.12 International Flavors & Fragrances
  68. 8.12.1 International Flavors & Fragrances Company Information
  69. 8.12.2 International Flavors & Fragrances Business Overview
  70. 8.12.3 International Flavors & Fragrances Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 International Flavors & Fragrances Pharma Sustained Release Agent Product Portfolio
  72. 8.12.5 International Flavors & Fragrances Recent Developments
  73. 8.13 Gattefosse
  74. 8.13.1 Gattefosse Company Information
  75. 8.13.2 Gattefosse Business Overview
  76. 8.13.3 Gattefosse Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Gattefosse Pharma Sustained Release Agent Product Portfolio
  78. 8.13.5 Gattefosse Recent Developments
  79. 8.14 Evonik Industries
  80. 8.14.1 Evonik Industries Company Information
  81. 8.14.2 Evonik Industries Business Overview
  82. 8.14.3 Evonik Industries Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Evonik Industries Pharma Sustained Release Agent Product Portfolio
  84. 8.14.5 Evonik Industries Recent Developments
  85. 8.15 Croda International
  86. 8.15.1 Croda International Company Information
  87. 8.15.2 Croda International Business Overview
  88. 8.15.3 Croda International Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Croda International Pharma Sustained Release Agent Product Portfolio
  90. 8.15.5 Croda International Recent Developments
  91. 8.16 BASF
  92. 8.16.1 BASF Company Information
  93. 8.16.2 BASF Business Overview
  94. 8.16.3 BASF Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 BASF Pharma Sustained Release Agent Product Portfolio
  96. 8.16.5 BASF Recent Developments
  97. 8.17 Ashland Global
  98. 8.17.1 Ashland Global Company Information
  99. 8.17.2 Ashland Global Business Overview
  100. 8.17.3 Ashland Global Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Ashland Global Pharma Sustained Release Agent Product Portfolio
  102. 8.17.5 Ashland Global Recent Developments
  103. 8.18 Allergan
  104. 8.18.1 Allergan Company Information
  105. 8.18.2 Allergan Business Overview
  106. 8.18.3 Allergan Pharma Sustained Release Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Allergan Pharma Sustained Release Agent Product Portfolio
  108. 8.18.5 Allergan Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pharma Sustained Release Agent Value Chain Analysis
  2. 9.1.1 Pharma Sustained Release Agent Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pharma Sustained Release Agent Production Mode & Process
  6. 9.2 Pharma Sustained Release Agent Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pharma Sustained Release Agent Distributors
  9. 9.2.3 Pharma Sustained Release Agent Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst